U.S. Government Supports Entegrion with $2M

Entegrion of Research Triangle Park received a $2 million federal award to continue developing its infusible hemostatic agent, Stasix, to control internal hemorrhage in trauma and surgical applications. Entegrion is expected to bring its first product, the Stasilon hemostatic wound dressing, to market later this year.